Accelerator-Based Stereotactic Radiosurgery for Brainstem Metastases

• DOI: 10.1227/neu.0b013e31823c40fe
• Publication Date: 2011-10-13T09:18:18Z
• Authors: Chun-Shu Lin; Michael T. Selch; Steve P. Lee; Jeffrey K. Wu; Furen Xiao; David S. Hong; Chien-Hua Chen; Aamir Hussain; Percy P. Lee; Antonio A. De Salles
• Keywords: Univariate analysis

Stereotactic radiosurgery represents a noninvasive alternative treatment for intracranial metastases.To investigate the outcome of linear accelerator-based stereotactic (linac-SRS) brainstem metastases.We retrospectively reviewed our database patients who were diagnosed with metastases and underwent linac-SRS between 1997 2008 at University California, Los Angeles.A total 45 48 treated. The median target volume was 0.40 mL (range, 0.02-5.70 mL), prescription dose 14 Gy 10-17 Gy) 90% isodose curve. survival time 11.6 months. Longer associated higher Karnofsky performance status. local control rate 92% 6 months 88% 1 year. Univariate analysis demonstrated significant relationship tumor (≤0.4 vs >0.4 mL, P = .023) SRS mode (conventional circular arc dynamic conformal arc, .044). There trend toward improved >14 (P .059). Two had complications following treatment, complication 4.7% 2 years. Serious morbidity occurred 17 Gy.Linac-SRS using provided excellent in less than 0.4 relatively low serious morbidity. results study support use metastases. We advocate to 16 Gy, given high this dose.